Apogee Therapeutics APGE Institutional Ownership

These investors collectively held 90.2% of Apogee Therapeutics's outstanding shares in June 2026, down from 113.4% in March 2026.

• They decreased total shares held in Apogee Therapeutics by -1.83% from last quarter, and the number of investors in APGE increased 62.36% annually.
• Activity in APGE broke down as 201 buyers, 66 sellers, and 22 unchanged among 289 total holders.
• Altogether, these fund groups held 68.01Mn shares in APGE by June 2026, down by 1.27Mn shares quarter on quarter, and up 11.22Mn shares year over year.
• Venrock Adviser, LLC leads ownership in APGE with 8.49Mn shares as of June 30, 2026, equal to 11.26% of outstanding shares.
• The largest buyers of Apogee Therapeutics for the quarter ending June 2026 were HBK INVESTMENTS L P (2.85Mn), GLAZER CAPITAL, LLC (1.64Mn), Pentwater Capital Management LP (1.42Mn), BlackRock, Inc. (1.42Mn), MILLENNIUM MANAGEMENT LLC (1.4Mn).
• The biggest sellers of Apogee Therapeutics for the quarter ending June 2026 included T. Rowe Price Investment Management, Inc. (9.54Mn), FMR LLC (6.77Mn), WELLINGTON MANAGEMENT GROUP LLP (3.81Mn), UBS Group AG (942.5K), PRICE T ROWE ASSOCIATES INC /MD/ (905.94K).
• Per Business Quant data, the top 10 holders of Apogee Therapeutics for the quarter ending June 2026 are Venrock Adviser, LLC (8.49Mn), BlackRock, Inc. (5.51Mn), HBK INVESTMENTS L P (2.85Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.57Mn), FMR LLC (2.49Mn), State Street Corp (2.3Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (1.74Mn), Goldman Sachs Group Inc (1.69Mn), BALYASNY ASSET MANAGEMENT L.P. (1.67Mn), GLAZER CAPITAL, LLC (1.64Mn).